This was a rather canny ad campaign from Progressive a little while back, but it grows out of something that the big insurers and actuarial community has been b

This was a rather canny ad campaign from Progressive a little while back, but it grows out of something that the big insurers and actuarial community has been becoming more agitated about over the past five to ten years, which is that the forecasts for life expectancy are becoming every more hedged with uncertainty. The people in that industry are very aware that there is great uncertainty in the development trajectory of aging-related biotechnologies over the next twenty years. Any time now a collection of therapies could be developed to add a decade or two to life spans. A combination of senescent cell clearance (demonstrated in mice), immune rejuvenation through either selective destruction of cluttered bad immune cells (demonstrated in mice) or thymic regeneration (demonstrated in mice), and next generation stem cell therapies (demonstrated in mice) might do the trick if it turns out that accumulation of metabolic waste (amyloid, cross-links, lipofuscin) is less important than thought. For example.